$423 Million is the total value of Fairmount Funds Management LLC's 22 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Buy | INSMED INC | $45,796,000 | +28.0% | 1,948,784 | +48.4% | 10.83% | -8.2% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $40,955,000 | +88.3% | 1,182,307 | +59.1% | 9.68% | +35.1% |
| ARGX | Buy | ARGENX SEsponsored adr | $39,175,000 | +42.2% | 124,244 | +58.0% | 9.26% | +2.0% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $39,013,000 | +450.5% | 942,571 | +402.4% | 9.22% | +294.9% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $33,402,000 | +15.3% | 469,264 | +21.1% | 7.90% | -17.3% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO | $28,375,000 | +270.0% | 239,314 | +330.1% | 6.71% | +165.4% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $28,018,000 | +188.0% | 1,156,817 | +177.5% | 6.62% | +106.6% |
| KROS | Buy | KEROS THERAPEUTICS INC | $21,584,000 | +26.0% | 396,911 | +35.5% | 5.10% | -9.7% |
| Buy | NUVALENT INC | $18,590,000 | +6.8% | 1,338,393 | +46.3% | 4.40% | -23.4% | |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $18,431,000 | +116.6% | 2,312,523 | +52.2% | 4.36% | +55.4% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $17,456,000 | -6.5% | 944,092 | 0.0% | 4.13% | -32.9% | |
| Buy | TYRA BIOSCIENCES INC | $13,749,000 | +51.4% | 1,284,990 | +99.1% | 3.25% | +8.6% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $13,598,000 | +61.5% | 4,133,237 | +65.4% | 3.22% | +15.9% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $13,024,000 | – | 549,988 | +100.0% | 3.08% | – |
| COGT | COGENT BIOSCIENCES INC | $11,677,000 | -12.7% | 1,558,975 | 0.0% | 2.76% | -37.4% | |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $11,371,000 | – | 2,669,300 | +100.0% | 2.69% | – |
| TIL | INSTIL BIO INC | $7,244,000 | -37.2% | 673,905 | 0.0% | 1.71% | -54.9% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $6,487,000 | -12.8% | 389,588 | 0.0% | 1.53% | -37.4% | |
| ASTRIA THERAPEUTICS INC | $6,118,000 | +24.5% | 911,736 | 0.0% | 1.45% | -10.7% | ||
| VRNA | VERONA PHARMA PLCsponsored ads | $4,624,000 | -25.7% | 926,602 | 0.0% | 1.09% | -46.8% | |
| ANNX | New | ANNEXON INC | $3,410,000 | – | 1,249,143 | +100.0% | 0.81% | – |
| ALLK | ALLAKOS INC | $838,000 | -41.8% | 147,189 | 0.0% | 0.20% | -58.3% | |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -2,502,259 | -100.0% | -13.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.